iC9-CAR19 T cells

Phase 1

UUNC Lineberger Comprehensive Cancer Center

iC9-CAR19 T cells is one of 41 therapeutic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

LymphomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2040

Phase 1Active, not recruiting

Lymphoma

NCT03696784

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03696784·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for iC9-CAR19 T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for iC9-CAR19 T cells. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUNC Lineberger Comprehensive Cancer Center

iC9-CAR19 T cells

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2040

Trials by Indication[1]

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News